Subscribe to NN1250-4129 A multi-centre, prospective, open-label, single-arm, non-interventional, post marketing surveillance (PMS) study of Tresiba® (insulin degludec) to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India